Skip to content
Login Register

#antibody production

11 public questions tagged with this topic.

Immunological Applications

Myeloma cells used in hybridoma technology are selected to be:

Establishing stringent selection requires myeloma background auxotrophic for purine salvage, achieved by exposure to 8-azaguanine, purine analogue structurally similar to guanine. Salvage competent cells convert 8-azaguanine via HGPRT to 8-azaguanosine monophosphate incorporated into mRNA and rRNA causing miscoding, translational errors, and lethal proteotoxicity triggering unfolded protein response. Spontaneous HPRT1 mutants survive because they cannot metabolize analogue, accumulating no toxic nucleotides. Surviving subclones harbor frameshift, nonsense, or missense mutations in coding exons 2-9, leading to premature stop codon and nonsense mediated mRNA decay, enzymatic activity undetectable via radiometric assay. In complete medium containing folate, deficiency tolerated because de novo purine synthesis via amidophosphoribosyltransferase using glutamine nitrogen supplies sufficient IMP via ten-step pathway. Once switched to HAT where aminopterin blocks that pathway, reliance shifts entirely to salvage, now impossible in mutants. ATP depletion, accumulation of PRPP, activation of AMPK, inhibition of mTORC1, and caspase 9 mediated apoptosis eliminate myeloma. Clones SP2/0-Ag14, P3X63-Ag8.653 routinely used worldwide ensure background below 1 per million, maximizing hybrid recovery efficiency.

Ref: Szybalski & Szybalska 1962 HGPRT negative mutants 8-azaguanine; ATCC SP2/0 Ag14 datasheet selection mechanism.

View Details
Immunological Applications

HAT medium contains:

HAT selective medium developed by John Littlefield in 1964 exploits metabolic auxotrophy to isolate somatic hybrids based on nucleotide salvage capability. Base medium DMEM or RPMI supplemented with fetal bovine serum provides carbon source, but three selective additives define HAT: hypoxanthine at 100 micromolar serving as purine base for salvage via hypoxanthine-guanine phosphoribosyltransferase converting to inosine monophosphate using phosphoribosyl pyrophosphate donor, thymidine at 16 micromolar supplying pyrimidine salvage substrate for thymidine kinase isoforms TK1 cytosolic and TK2 mitochondrial phosphorylating to thymidine monophosphate, and aminopterin at 0.4 micromolar acting as high-affinity folate antagonist. Aminopterin binds dihydrofolate reductase at picomolar Ki, preventing regeneration of tetrahydrofolate required for one-carbon transfer reactions in purine ring biosynthesis and thymidylate formation. De novo nucleotide synthesis collapses causing dNTP pool depletion, replication fork stalling,ATR mediated checkpoint activation, and S phase arrest. Only cells expressing both salvage enzymes bypass block by recycling exogenous bases, creating powerful negative selection for hybrids while eliminating auxotrophic myeloma background that lacks HGPRT.

Ref: Littlefield Science 1964 145:709 HAT selection; Szybalski Biochem Pharmacol HAT hypoxanthine aminopterin thymidine composition.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary plasma cells cannot be cultured long term because they activate intrinsic mitochondrial apoptosis via Bim upregulation when removed from survival niche provided by stromal cell contact, interleukin-6, and BAFF, plus replicative senescence triggered by telomere shortening each division. Myeloma cells circumvent these barriers through multiple oncogenic lesions: expression of hTERT telomerase reverse transcriptase adding TTAGGG repeats preventing crisis, disruption of p53-MDM2 axis, loss of cyclin dependent kinase inhibitors p16 and p21, autocrine loops via IGF-1 and interleukin-6 constitutively activating JAK-STAT3, and anti-apoptotic proteins Bcl-2, Mcl-1, Bcl-xL sequestering Bax-Bak. Metabolically they exhibit enhanced aerobic glycolysis and glutaminolysis supporting high rate immunoglobulin synthesis of 20 to 50 picograms per cell per day needed for commercial manufacture. Specificity remains encoded entirely by B cell derived VDJ sequences while unlimited division derives solely from tumor genome. Without immortality contribution, antibody secreting clones exhaust after few doublings, master cell banking for regulatory filing impossible, and large-scale therapeutic production economically unfeasible, underscoring myeloma purpose for perpetuating culture.

Ref: Freshney Culture Animal Cells 7th ed myeloma immortality hTERT; Abbas Cellular Molecular Immunology hybridoma immortalization.

View Details
Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary B lymphocytes after differentiation short-lived plasma cells produce Ig extraordinary rate but survive 3-5 days culture due activation-induced death mediated Fas upregulation after strong BCR crosslinking and lack telomere maintenance somatic cells lacking telomerase entering senescence limited divisions dependence extrinsic survival signals CD40L helper T cells cytokines IL-4 IL-6 IL-21 follicular helper. Continuous monoclonal manufacturing over months requires immortalization essential. Myeloma plasmacytoma malignant transformation plasma cells proliferate indefinitely without exogenous growth factors due translocation placing oncogene c-myc under IgH enhancer driving cyclin D and constitutive IL-6 secretion creating autocrine loop activating JAK-STAT pathway promoting survival proliferation. Fusion with B cell transfers transformation phenotype granting hybridoma sustained division >100 passages cryopreservation stability preserving viability liquid nitrogen storage ability grow serum-free chemically defined bioreactors scaled 2000 L robust ER comprising chaperone BiP protein disulfide isomerase folding heavy light chains efficiently. While antibody specificity derives entirely B-cell partner rearranged Ig loci longevity continuous secretion originate myeloma component overcoming natural mortality limitation enabling long-term production and banking hybridoma lines.

Ref: Kohler Milstein Myeloma Immortality Principle 1975; Lodish Hybridoma Immortalization Mechanism Biology; Janeway Myeloma Fusion Purpose Immunobiology Chapter 2.

View Details
Immunological Applications

Hybridoma technology involves fusion of:

Somatic cell fusion underlying hybridoma merges two differentiated cell types each contributing specialized traits necessary monoclonal antibody manufacturing. Antigen-experienced B lymphocyte harvested spleen four days after final booster carries functionally rearranged Ig heavy VDJ and light VJ genes formed RAG1/RAG2 recombination junctional diversity somatic hypermutation conferring high affinity specificity target epitope active transcription intronic enhancer Emu 3 prime regulatory region capacity synthesizing Ig up to 2000 molecules per second but limited lifespan due lack telomerase dependence T-cell help CD40L IL-4 IL-21 undergoing Fas-FasL activation-induced cell death few divisions. Plasmacytoma myeloma line P3X63Ag8.653 lacking HPRT enzyme secreting no endogenous Ig provides immortal growth due chromosomal translocation t(12;15) placing c-myc under IgH enhancer driving continuous cycle plus HAT selection sensitivity enabling elimination unfused myeloma. PEG induced membrane fusion allows cytoplasmic mixing forming heterokaryon subsequently nuclear fusion mitotic segregation retaining chromosomes encoding antibody variable regions B cell while myeloma chromosomes sustain uncontrolled proliferation. Selection eliminates unfused myeloma primary B cells permitting only hybridoma colonies producing monoclonal antibody exquisite specificity and immortality essential scale manufacturing.

Ref: Janeway Hybridoma Fusion B cell Myeloma Mechanism 9th ed; Alberts Cell Fusion Mechanism Chapter 19; NCBI Kohler Milstein Hybridoma Methodology Original.

View Details
Immunological Applications

Monoclonal antibodies are produced by:

Monoclonal antibodies originate immortalized hybridoma lines fusing single antibody-secreting B lymphocyte with myeloma partner preserving exactly one immunoglobulin gene rearrangement producing uniform paratope. Protocol begins immunization BALB/c mice purified antigen HER2 extracellular domain mixed Freund's adjuvant stimulating germinal center spleen. Four days after final booster splenocytes enriched plasma blasts expressing high-affinity surface IgG harvested. Fusion mediated PEG 1500 or electrofusion aligning cells pearl chains creates heterokaryons containing nuclei both parents tetraploid genome combining proliferative machinery myeloma P3X63Ag8U deficient HPRT and functional Ig heavy light chain variable regions B cell. Screening supernatants 10 days HAT medium ELISA identifies wells secreting antibody binding desired epitope single specificity affinity parent clone e.g., 10 nM. Cloning limiting dilution ensures monoclonality 0.5 cell per well. Resulting hybridoma inherits indefinite division activated c-myc autocrine IL-6 robust ER chaperone capacity folding continuous Ig secretion under Ig enhancers. Bioreactor expansion yields liters supernatant purified Protein A affinity chromatography producing uniform reagent defined sequence enabling therapeutics trastuzumab rituximab derived hybridoma technology now adapted recombinant CHO expression systems large-scale manufacturing.

Ref: Kohler and Milstein Nature 1975 Hybridoma Monoclonal Generation; Janeway Hybridoma Technology Production Chapter 5; Lodish Antibody Production Hybridoma Cells Method.

View Details
Immunological Applications

Polyclonal antibodies differ from monoclonal antibodies because they:

Polyclonal antibody preparations heterogeneous mixture immunoglobulin molecules diverse B lymphocyte clones responding complex immunogen multiple antigenic determinants repetitive epitopes. Each naive B cell generates unique BCR random recombination RAG-mediated VDJ joining heavy chain variable diversity joining segments VJ joining light chain kappa lambda diversified junctional addition non-templated nucleotides TdT and somatic hypermutation germinal centers introducing point mutations rate 10^-3 per base division selecting higher affinity via follicular dendritic cell presentation. Immunization whole bacteria S. aureus viral glycoprotein influenza hemagglutinin toxoid tetanus toxoid containing repetitive carbohydrates conformational proteins activates numerous clones secreting IgG subclasses IgG1 IgG2 affinities 10^-6 to 10^-11 molar avidities multivalency. Serum contains antibodies recognizing linear peptide epitopes 8-12 residues discontinuous conformational surfaces formed distant residues folded together carbohydrate moieties neoepitopes formaldehyde treatment. Polyepitopic recognition enhances lattice formation C1q classical complement activation improving pathogen agglutination opsonization phagocytosis although batch variability cross-reactivity homologous antigens limited reproducibility complicate standardization compared monoclonal reagents uniform specificity.

Ref: Janeway Immunobiology 9th ed Polyclonal vs Monoclonal Diversity Chap 5; NCBI Bookshelf Antibody Diversity Mechanism; Campbell Immunology Antibody Response Polyepitopic.

View Details
Basic Applied Biology

HAT medium selects hybridoma cells based on:

HAT medium selection developed by John Littlefield in 1964 exploits differential nucleotide anabolism pathways to isolate hybrid cells from mixture of parental populations. De novo purine and pyrimidine synthesis requires tetrahydrofolate-dependent enzymes, specifically aminopterin, a folate analog, competitively inhibits dihydrofolate reductase DHFR blocking de novo pathway. Alternative salvage pathway recycles hypoxanthine via hypoxanthine-guanine phosphoribosyltransferase HGPRT converting to IMP and thymidine via thymidine kinase TK to TMP, bypassing blocked de novo routes. Myeloma partners engineered to lack HGPRT through 8-azaguanine selection or TK deficiency via bromodeoxyuridine selection cannot utilize salvage and therefore die in HAT containing hypoxanthine, aminopterin and thymidine. B lymphocytes naturally express HGPRT and TK but are mortal in culture, senescing within days. Only hybrid cells inheriting immortal growth from myeloma and salvage enzymes from B cell survive after 10 to 14 days culture. Subsequent cloning by limiting dilution at 0.5 cell per well ensures monoclonality. This biochemical selection remains gold standard because de novo dependence versus salvage provides elegant genetic selection mechanism.

Ref: Littlefield Science 1964 Selection of hybrids; Abbas Immunology 10th ed. HAT selection; Alberts Ch nucleotide metabolism salvage.

View Details
Basic Applied Biology

Hybridoma technology produces:

Hybridoma technology developed by Georges Köhler and César Milstein in 1975 and awarded Nobel 1984 created paradigm shift by immortalizing antibody-producing B lymphocytes through somatic cell fusion. Mice immunized with antigen develop germinal center reaction where B cells undergo VDJ recombination, somatic hypermutation and class switching to generate high affinity plasma cells. Splenic lymphocytes harvested shortly after boost are fused with HGPRT-deficient myeloma partner such as SP2/0-Ag14 or NS0 using polyethylene glycol 1500 that perturbs lipid bilayers promoting membrane fusion forming heterokaryons containing nuclei from both parents. Resulting hybrid cells combine immortal growth driven by myeloma oncogenes like c-myc deregulation with functional immunoglobulin heavy and light chain transcription from B cell. Clonal expansion and selection yields everlasting lines secreting monospecific antibody of defined isotype typically IgG1 kappa recognizing single epitope, known as monoclonal antibody. Such reagents revolutionized diagnostics, research tools like western blotting, and therapeutics by提供 unlimited standardized antibody with consistent affinity replacing heterogeneous polyclonal sera plagued by batch variation.

Ref: Köhler & Milstein Nature 1975 Continuous cultures of fused cells; Abbas Cellular and Molecular Immunology 10th ed. monoclonal antibody generation.

View Details